{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T20:29:54Z","timestamp":1726518594975},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T00:00:00Z","timestamp":1384214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.jcf.2013.04.014","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T13:16:16Z","timestamp":1371129376000},"page":"547-558","source":"Crossref","is-referenced-by-count":10,"title":["Drug induced complications; can we do more?"],"prefix":"10.1016","volume":"12","author":[{"given":"Daniel","family":"Peckham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8889","key":"10.1016\/j.jcf.2013.04.014_bb0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0140-6736(94)90817-6","article-title":"Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes","volume":"343","author":"Smyth","year":"1994","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jcf.2013.04.014_bb0010","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ibd.20830","article-title":"Fibrosing colonopathy associated with treatment with enteric-coated mesalazine pills","volume":"15","author":"Prieto","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jcf.2013.04.014_bb0495","article-title":"Fibrosing colonopathy associated with pancreatic enzymes","volume":"21","author":"Medicine CoSo","year":"1995","journal-title":"Curr Probl Pharmacovigil"},{"issue":"6","key":"10.1016\/j.jcf.2013.04.014_bb0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcf.2008.05.008","article-title":"Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD)","volume":"7","author":"van den Berg","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1399-5448.2011.00810.x","article-title":"Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial","volume":"13","author":"Minicucci","year":"2012","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"10.1016\/j.jcf.2013.04.014_bb0500","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/adc.2010.204636","article-title":"Once daily insulin detemir in cystic fibrosis with insulin deficiency","volume":"97","author":"Hameed","year":"2012","journal-title":"Arch Dis Child"},{"issue":"8","key":"10.1016\/j.jcf.2013.04.014_bb0035","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2337\/dc09-0212","article-title":"Effects of acute insulin-induced hypoglycemia on spatial abilities in adults with type 1 diabetes","volume":"32","author":"Wright","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.jcf.2013.04.014_bb0040","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/thx.2010.157883","article-title":"Treatment recommendations for cystic fibrosis-related diabetes: too little, too late?","volume":"66","author":"Nathan","year":"2011","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.jcf.2013.04.014_bb0045","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jcf.2013.04.014_bb0505","first-page":"CD004730","article-title":"Insulin and oral agents for managing cystic fibrosis-related diabetes","author":"Onady","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.jcf.2013.04.014_bb0055","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00125-011-2174-9","article-title":"Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial","volume":"54","author":"van Raalte","year":"2011","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.jcf.2013.04.014_bb0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00431-006-0198-9","article-title":"Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients?","volume":"166","author":"De Boeck","year":"2007","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0510","first-page":"CD000407","article-title":"Oral steroids for cystic fibrosis","author":"Cheng","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ppul.20333","article-title":"Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis","volume":"41","author":"Thomson","year":"2006","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2013.04.014_bb0075","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ppul.21002","article-title":"Omalizumab for treatment of ABPA exacerbations in CF patients","volume":"44","author":"Lebecque","year":"2009","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2013.04.014_bb0080","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/02770900902849871","article-title":"Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach","volume":"46","author":"Randhawa","year":"2009","journal-title":"J Asthma"},{"key":"10.1016\/j.jcf.2013.04.014_bb0515","first-page":"CD002010","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","volume":"4","author":"Conwell","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jcf.2013.04.014_bb0090","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jcf.2011.07.007","article-title":"Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis","volume":"10","author":"Haworth","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2013.04.014_bb0095","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1183\/09031936.00077210","article-title":"Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis","volume":"37","author":"De Boeck","year":"2011","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2013.04.014_bb0100","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jpeds.2008.07.010","article-title":"Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis","volume":"153","author":"Ren","year":"2008","journal-title":"J Pediatr"},{"issue":"11","key":"10.1016\/j.jcf.2013.04.014_bb0105","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/thx.2006.061366","article-title":"Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria","volume":"61","author":"Block","year":"2006","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.jcf.2013.04.014_bb0110","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1164\/rccm.200511-1808OC","article-title":"Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis","volume":"173","author":"Balfour-Lynn","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.jcf.2013.04.014_bb0115","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/thorax.57.8.749","article-title":"Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis","volume":"57","author":"Parmar","year":"2002","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1569-1993(03)00022-5","article-title":"Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450","volume":"2","author":"De Wachter","year":"2003","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0125","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0031-3955(16)33069-3","article-title":"Cystic fibrosis: a not-so-fatal disease","volume":"21","author":"Crozier","year":"1974","journal-title":"Pediatr Clin North Am"},{"issue":"3","key":"10.1016\/j.jcf.2013.04.014_bb0130","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jpeds.2005.06.003","article-title":"Overweight and obesity in deltaF508 homozygous cystic fibrosis","volume":"147","author":"Kastner-Cole","year":"2005","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.jcf.2013.04.014_bb0135","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcf.2012.03.006","article-title":"LDL-cholesterol and insulin are independently associated with body mass index in adult cystic fibrosis patients","volume":"11","author":"Coderre","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2013.04.014_bb0520","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3109\/07853890.2011.605387","article-title":"Mapping body fat distribution: a key step towards the identification of the vulnerable patient?","volume":"44","author":"Arsenault","year":"2012","journal-title":"Ann Med"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jcf.2010.12.001","article-title":"The effect of exercise on large artery haemodynamics in cystic fibrosis","volume":"10","author":"Hull","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"352","key":"10.1016\/j.jcf.2013.04.014_bb0525","first-page":"685","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"21","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcf.2013.04.014_bb0155","first-page":"f36","article-title":"Rheumatoid arthritis and heart disease","volume":"113","author":"Nicholls","year":"2006","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.jcf.2013.04.014_bb0160","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa040967","article-title":"Inflammatory markers and the risk of coronary heart disease in men and women","volume":"351","author":"Pai","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcf.2013.04.014_bb0165","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1651-2227.1987.tb17271.x","article-title":"Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients","volume":"76","author":"Pedersen","year":"1987","journal-title":"Acta Paediatr Scand"},{"issue":"5","key":"10.1016\/j.jcf.2013.04.014_bb0170","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/thorax.55.5.355","article-title":"Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs","volume":"55","author":"Elborn","year":"2000","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.jcf.2013.04.014_bb0175","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/MCP.0b013e32833eebfd","article-title":"Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity","volume":"16","author":"Prayle","year":"2010","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.jcf.2013.04.014_bb0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2006.05.013","article-title":"Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics","volume":"6","author":"Etherington","year":"2007","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0530","first-page":"CD002007","article-title":"Single versus combination intravenous antibiotic therapy for people with cystic fibrosis","author":"Elphick","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jcf.2013.04.014_bb0190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.prrv.2007.04.005","article-title":"Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms","volume":"8","author":"Aaron","year":"2007","journal-title":"Paediatr Respir Rev"},{"issue":"1","key":"10.1016\/j.jcf.2013.04.014_bb0535","first-page":"CD002009","article-title":"Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis","author":"Smyth","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcf.2006.05.015","article-title":"Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis-caution with trough concentrations","volume":"6","author":"Coulthard","year":"2007","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2013.04.014_bb0205","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1164\/rccm.201001-0057OC","article-title":"Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes","volume":"182","author":"Collaco","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2013.04.014_bb0210","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0215","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1378\/chest.128.2.545","article-title":"Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia","volume":"128","author":"Panidis","year":"2005","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0220","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/BF01644140","article-title":"Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree (review)","volume":"15","author":"Bergogne-Berezin","year":"1987","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.jcf.2013.04.014_bb0540","first-page":"CD001021","article-title":"Inhaled antibiotics for long-term therapy in cystic fibrosis","author":"Ryan","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jcf.2013.04.014_bb0545","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1542-4758.2012.00675.x","article-title":"Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis","volume":"16","author":"Florescu","year":"2012","journal-title":"Hemodial Int"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0235","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jcf.2010.03.007","article-title":"Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis","volume":"9","author":"Guy","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2013.04.014_bb0240","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1155\/2008\/202464","article-title":"A pilot study to compare tobramycin 80mg injectable preparation with 300mg solution for inhalation in cystic fibrosis patients","volume":"15","author":"Nikolaizik","year":"2008","journal-title":"Can Respir J"},{"issue":"9","key":"10.1016\/j.jcf.2013.04.014_bb0245","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2013.04.014_bb0250","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","article-title":"A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis","volume":"20","author":"Hodson","year":"2002","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2013.04.014_bb0255","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0260","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/14992027.2010.524253","article-title":"Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: a study using extended high-frequency audiometry and distortion product otoacoustic emissions","volume":"50","author":"Al-Malky","year":"2011","journal-title":"Int J Audiol"},{"issue":"12","key":"10.1016\/j.jcf.2013.04.014_bb0265","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/FPC.0b013e328312b072","article-title":"Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population","volume":"18","author":"Conrad","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"24","key":"10.1016\/j.jcf.2013.04.014_bb0550","first-page":"930","article-title":"Assessment of the nephrotoxicity of amikacin in patients with cystic fibrosis","volume":"122","author":"Hugli","year":"1992","journal-title":"Schweiz Med Wochenschr"},{"issue":"6","key":"10.1016\/j.jcf.2013.04.014_bb0275","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/AAC.9.6.956","article-title":"Ototoxicity of amikacin","volume":"9","author":"Black","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0280","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1440-1754.1998.00197.x","article-title":"Antibiotic hypersensitivity reactions in cystic fibrosis","volume":"34","author":"Wills","year":"1998","journal-title":"J Paediatr Child Health"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0285","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1378\/chest.106.4.1124","article-title":"Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis","volume":"106","author":"Pleasants","year":"1994","journal-title":"Chest"},{"issue":"Suppl. 7","key":"10.1016\/j.jcf.2013.04.014_bb0290","doi-asserted-by":"crossref","first-page":"S608","DOI":"10.1093\/clinids\/13.Supplement_7.S608","article-title":"Retrospective clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses","volume":"13","author":"Koch","year":"1991","journal-title":"Rev Infect Dis"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0555","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jcf.2012.01.007","article-title":"The use of nebulised aztreonam lysine (AZLI) in aztreonam hypersensitive patients","volume":"11","author":"Whitaker","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2013.04.014_bb0300","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1021\/tx100151v","article-title":"Drug metabolite-specific lymphocyte responses in sulfamethoxazole allergic patients with cystic fibrosis","volume":"23","author":"Lavergne","year":"2010","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"10.1016\/j.jcf.2013.04.014_bb0305","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4049\/jimmunol.1100647","article-title":"Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis","volume":"187","author":"Whitaker","year":"2011","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.jcf.2013.04.014_bb0560","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jaci.2010.12.1119","article-title":"Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis","volume":"127","author":"Elsheikh","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jcf.2013.04.014_bb0565","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/jpet.111.190900","article-title":"Characterization of the antigen specificity of T-cell clones from piperacillin hypersensitive patients with cystic fibrosis","volume":"341","author":"El-Ghaiesh","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0320","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaci.2005.10.030","article-title":"Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions","volume":"117","author":"Beeler","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0325","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2011.02.002","article-title":"Rapid desensitization for non-immediate reactions in patients with cystic fibrosis","volume":"10","author":"Whitaker","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0330","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1081-1206(10)61778-4","article-title":"Antibiotic desensitization for the allergic patient: 5years of experience and practice","volume":"92","author":"Turvey","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.jcf.2013.04.014_bb0570","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jcf.2009.08.002","article-title":"A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity","volume":"8","author":"Legere","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2013.04.014_bb0340","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1440-1843.2003.00461.x","article-title":"Antibiotic desensitization in adults with cystic fibrosis","volume":"8","author":"Burrows","year":"2003","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0345","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/jac\/39.4.556","article-title":"Intravenous desensitization to ceftazidime in cystic fibrosis patients","volume":"39","author":"Ghosal","year":"1997","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 46","key":"10.1016\/j.jcf.2013.04.014_bb0350","first-page":"13","article-title":"Candida albicans infection in adults with cystic fibrosis","volume":"99","author":"Webb","year":"2006","journal-title":"J R Soc Med"},{"issue":"1","key":"10.1016\/j.jcf.2013.04.014_bb0575","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcf.2012.05.007","article-title":"Recurrent Clostridium difficile colitis in cystic fibrosis: an emerging problem","volume":"12","author":"Egressy","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2013.04.014_bb0360","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.ajkd.2005.06.003","article-title":"Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis","volume":"46","author":"Hoppe","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0365","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhin.2008.01.004","article-title":"Water filters can prevent Stenotrophomonas maltophilia contamination of nebuliser equipment used by people with cystic fibrosis","volume":"68","author":"Woodhouse","year":"2008","journal-title":"J Hosp Infect"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0370","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2214.2006.00669.x","article-title":"Microbial contamination of nebulizers in the home treatment of cystic fibrosis","volume":"33","author":"Blau","year":"2007","journal-title":"Child Care Health Dev"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0580","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jcf.2012.02.004","article-title":"Bloodstream infections in cystic fibrosis: nine years of experience in both adults and children","volume":"11","author":"Cargill","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2013.04.014_bb0380","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1308\/003588408X321684","article-title":"Totally implantable venous access devices \u2014 20years' experience of implantation in cystic fibrosis patients","volume":"90","author":"Royle","year":"2008","journal-title":"Ann R Coll Surg Engl"},{"issue":"13","key":"10.1016\/j.jcf.2013.04.014_bb0385","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"issue":"9338","key":"10.1016\/j.jcf.2013.04.014_bb0390","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jcf.2013.04.014_bb0395","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/thorax.57.3.212","article-title":"Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial","volume":"57","author":"Wolter","year":"2002","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jcf.2013.04.014_bb0400","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jac\/dkq425","article-title":"Characterization of macrolide resistance genes in Haemophilus influenzae isolated from children with cystic fibrosis","volume":"66","author":"Roberts","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jcf.2013.04.014_bb0405","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcf.2008.09.001","article-title":"Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients","volume":"8","author":"Hansen","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2013.04.014_bb0410","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1172\/JCI46095","article-title":"Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection","volume":"121","author":"Renna","year":"2011","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0585","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jcf.2012.02.005","article-title":"Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis","volume":"11","author":"Ren","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2013.04.014_bb0420","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200802-327OC","article-title":"Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis","volume":"178","author":"Dasenbrook","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"23","key":"10.1016\/j.jcf.2013.04.014_bb0425","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jcf.2013.04.014_bb0590","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1164\/ajrccm.179.8.734a","article-title":"The impact of MRSA on lung function in patients with cystic fibrosis","volume":"179","author":"Sawicki","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2013.04.014_bb0435","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1378\/chest.06-2756","article-title":"Panton\u2013Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis","volume":"131","author":"Elizur","year":"2007","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0440","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1128\/JCM.00255-09","article-title":"Prevalence of community-associated methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis","volume":"47","author":"Goodrich","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0445","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.05077-11","article-title":"High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole","volume":"56","author":"Burgel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jcf.2013.04.014_bb0450","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.jcf.2013.04.014_bb0455","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3109\/13693786.2010.503665","article-title":"Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France","volume":"48","author":"Paugam","year":"2010","journal-title":"Med Mycol"},{"key":"10.1016\/j.jcf.2013.04.014_bb0595","first-page":"CD002204","article-title":"Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","volume":"6","author":"Elphick","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jcf.2013.04.014_bb0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcf.2009.09.003","article-title":"Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy","volume":"9","author":"Zemanick","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2013.04.014_bb0470","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2013.04.014_bb0475","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pec.2008.08.027","article-title":"Adherence to nebulised antibiotics in cystic fibrosis","volume":"75","author":"Latchford","year":"2009","journal-title":"Patient Educ Couns"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0480","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1378\/chest.09-2940","article-title":"Prevalence of symptoms of anxiety and depression in German patients with cystic fibrosis","volume":"138","author":"Goldbeck","year":"2010","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.jcf.2013.04.014_bb0485","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2011.03.005","article-title":"Longitudinal association between medication adherence and lung health in people with cystic fibrosis","volume":"10","author":"Eakin","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2013.04.014_bb0490","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MCP.0b013e3283121cf1","article-title":"Prevalence and impact of depression in cystic fibrosis","volume":"14","author":"Quittner","year":"2008","journal-title":"Curr Opin Pulm Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199313000738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199313000738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T09:28:20Z","timestamp":1539595700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199313000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1569199313000738"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2013.04.014","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}